Willingness to pay for new Papanicolaou test technologies.
The amount of money a woman is willing to pay for liquid-based cytology technology has not been measured. In the present study, 175 women answered a questionnaire asking how much they would pay to decrease their risk of dying of cervical cancer if a new (liquid-based) Papanicolaou (Pap) test was used in place of the conventional smear. When women assumed that the new Pap test reduced the risk of dying of cervical cancer from 1 in 37,000 to 1 in 50,000, the mean amount they were willing to pay was $237. If women had more than 2 children, they were willing to pay more for the new Pap test than women with 2 or fewer children. These data indicate that liquid-based and conventional Pap tests are undervalued and that cost-effectiveness studies generally have not taken into account the preference of women for new Pap test technologies.
Raab
Stephen S
SS
Department of Pathology and Laboratory Medicine, Allegheny General Hospital, Pittsburgh, PA 15212, USA.
Grzybicki
Dana Marie
DM
Hart
Alison R
AR
Kiely
Sharon
S
Andrew-JaJa
Carey
C
Scioscia
Eugene
E
D001294:Attitude to Health; D003362:Cost-Benefit Analysis; D005260:Female; D005382:Financing, Personal; D017048:Health Care Costs; D006801:Humans; D007182:Income; D065006:Papanicolaou Test; D017060:Patient Satisfaction; D012051:Reimbursement Mechanisms; D011795:Surveys and Questionnaires; D002583:Uterine Cervical Neoplasms / Q000401:mortality / Q000517:prevention & control*; D014626:Vaginal Smears / Q000191:economics* / Q000379:methods* / Q000639:trends